Overall market sentiment has been high on BIO-TECHNE Corp (TECH) stock lately. TECH receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With TECH Stock Today?
BIO-TECHNE Corp (TECH) stock has fallen -4.46% while the S&P 500 has risen 0.22% as of 12:03 PM on Tuesday, Aug 4. TECH has fallen -$12.43 from the previous closing price of $278.87 on volume of 170,427 shares. Over the past year the S&P 500 has risen 16.07% while TECH has risen 33.56%. TECH earned $4.74 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 56.31.
To see InvestorsObserver's Sentiment Score for BIO-TECHNE Corp click here.
More About BIO-TECHNE Corp
Bio-Techne Corp is a life science manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The protein sciences division's key products (78% of sales) include proteins, antibodies, and assays as well as equipment and associated consumables for protein characterization and analysis. The remaining revenue in the diagnostics and genomics segment is roughly split between manufacturing creates controls, calibrators, and reagents for diagnostic manufacturers combined with proprietary molecular and genetic testing kits. The company is split into two reporting segments namely, Protein Sciences segment and Diagnostics and Genomics segment. The Protein Sciences segment generates maximum revenue for the company.
